Refractory GERD, beyond proton pump inhibitors

Curr Opin Pharmacol. 2018 Dec:43:99-103. doi: 10.1016/j.coph.2018.09.001. Epub 2018 Sep 18.

Abstract

Pharmacologic therapy, surgery, minimally invasive therapies, and alternative therapies are different options available for the management of refractory GERD. The choice may depend on the cause of refractoriness. Increased gastric acid suppression therapy might be useful in the rare patients with persistent elevated esophageal acid exposure on proton pump inhibitors (PPI). Potassium-competitive acid blockers (P-CAB) might induce a more important acid inhibition than PPI. Baclofen might act as a reflux inhibitor and demonstrates a significant efficacy in rumination syndrome. The role of topical antacid-alginate in refractory GERD might be limited. Surgery might be a valid option in case of persistent pathological acid esophageal exposure despite PPI. Further evaluation of minimally invasive procedures is necessary. Finally diet, diaphragmatic breathing and transcutaneous electrical acustimulation might be of interest in patients with esophageal hypersensivity or functional symptoms.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Decision-Making
  • Complementary Therapies
  • Digestive System Surgical Procedures* / adverse effects
  • Gastric Acid / metabolism*
  • Gastric Mucosa* / drug effects
  • Gastric Mucosa* / metabolism
  • Gastric Mucosa* / physiopathology
  • Gastric Mucosa* / surgery
  • Gastroesophageal Reflux / diet therapy
  • Gastroesophageal Reflux / metabolism
  • Gastroesophageal Reflux / physiopathology
  • Gastroesophageal Reflux / therapy*
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Hydrogen-Ion Concentration
  • Patient Selection
  • Proton Pump Inhibitors / therapeutic use
  • Risk Factors
  • Treatment Outcome

Substances

  • Gastrointestinal Agents
  • Proton Pump Inhibitors